{"id":475,"date":"2010-08-11T13:48:46","date_gmt":"2010-08-11T17:48:46","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=475"},"modified":"2010-08-14T09:32:03","modified_gmt":"2010-08-14T13:32:03","slug":"alectos-therapeutics-merck-collaborate-on-alzheimers-drug","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=475","title":{"rendered":"Alectos Therapeutics, Merck Collaborate on Alzheimer&#8217;s Drug"},"content":{"rendered":"<p><a href=\"http:\/\/www.alectos.com\/\">Alectos Therapeutics Inc.<\/a> in Burnaby, British Columbia, Canada will collaborate with global pharmaceutical company <a href=\"http:\/\/www.merck.com\/\">Merck &amp; Co.<\/a> to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme believed to be involved in the development of Alzheimer&#8217;s disease and other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop, and commercialize compounds that modulate this target.<\/p>\n<p>Under the agreement, Merck has paid Alectos for and will fund further research into Alectos&#8217; existing portfolio of compounds targeting Alzheimer&#8217;s disease. Alectos is eligible for up to US $289 million in fees, research, development, and regulatory milestones and tiered royalty payments on sales of any products resulting from this collaboration.<\/p>\n<p>Alectos and Merck will collaborate on drug discovery and preclinical development. Merck will handle clinical development and have worldwide marketing and commercialization rights to any resulting products.<\/p>\n<p>Alectos Therapeutics is a spin-off biotechnology company from Simon Fraser University that develops small-molecule drugs for serious and life-threatening human diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alectos Therapeutics Inc. in Burnaby, British Columbia, Canada will collaborate with global pharmaceutical company Merck &amp; Co. to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme believed to be involved in the development of Alzheimer&#8217;s disease and other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop, and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[79,21],"class_list":["post-475","post","type-post","status-publish","format-standard","hentry","category-ventures","tag-alzheimers","tag-biotech"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=475"}],"version-history":[{"count":5,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/475\/revisions"}],"predecessor-version":[{"id":518,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/475\/revisions\/518"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}